Nutra Pharma Analyst Report by Small Cap Traders and Issued by BrokerBank Securities, Inc.

TORONTO, Aug. 19, 2014

Nutra Pharma is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. It carries out basic drug discovery research and clinical development. Nutra Pharma, through its subsidiary, ReceptoPharm, manufactures over-the counter (OTC) drug products for the treatment of moderate to severe chronic pain named Nyloxin^®. It is also engaged in the research and development of novel anticholinergic therapeutic protein products for the treatment of autoimmune and neurologic disorders.  

An analyst report which details an overview of the company, financial and competitive analysis and analyst recommendation can be viewed in its entirety by using the link below. There is no cost obligation required to view this report: 

http://bit.ly/-NPHC-AnalystReport

Copy and paste to browser may be required.

FORWARD-LOOKING DISCLAIMER 

This report may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward- looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of mentioned company to be materially different from the statements made herein.